GlaxoSmithKline posts Q2FY22 consolidated PAT at Rs. 204.24 Cr

GlaxoSmithKline Pharmaceuticals Limited has reported consolidated financial results for the period ended September 30, 2021

Transforming Healthcare Through AI

Cipla consolidated net profit at Rs 711.36 cr. in Q2FY22

Cipla has reported consolidated financial results for the period ended September 30, 2021

Gland Pharma PAT declines to Rs 302 crore QoQ in Q2FY22

The company’s wide therapeutic portfolio helped to sustain growth despite changing market demand

Domestic growth to the fore as US weakness persists: ICICI Direct

ICICI Direct gives an update on the 12 companies that it has covered in the healthcare universe. A report

Hospitals to accelerate digital investments: Frost & Sullivan

The survey revealed that improving customer experience (CX) and operational efficiencies are top priorities, which healthcare organizations aim to attain by deploying digital health solutions

HealthEdge opens its facility in Pune

The Pune centre expands its presence beyond Bangalore and Hyderabad

Govt clarifies on export ban of syringes

Quantitative restrictions in place to meet domestic needs to cater to the vaccination programme

Aurobindo subsidiary submits MAA for oncology biosimilar

CuraTeQ Biologics is on track for filing a second oncology biosimilar

Ind-Ra predicts growth in US sales for Indian pharma from H2FY22

Price erosion, weak demand for acute portfolio and low ANDA approvals in the US weighed on the performance of Indian pharma in Q1FY22. However, the scenario is expected to change in H2FY22 when new approvals and inspections resume